Gp.ai

Primary care is under increasing pressure, rising patient demand, growing administrative burden and an urgent shift towards prevention‑led, personalised care. Dr Angus Perry, a practising GP, saw first‑hand how AI could help clinicians work differently: reducing cognitive load, surfacing meaningful insights from consultations, and freeing up time for patient care.

GPai’s challenge wasn’t the idea, it was how to turn that idea into something real. As an early‑stage venture, GPai had no capital to build an MVP, no access to enterprise‑grade delivery capability, and no clear pathway to clinical validation or follow‑on investment. Progress needed to be fast, but also credible, compliant and de‑risked.

Through Vivolution’s Venture Investment Programme, GPai accessed an integrated approach that combined investment, software delivery and commercial support from day one. Working in partnership with Deepbridge Capital and TES (an IBM Platinum Partner), Vivolution helped GPai move quickly while maintaining the standards required for healthcare technology.

The focus was on building the right product, grounded in real clinical workflows, designed with users, and architected for scale, security and compliance.

Within just 12 weeks, GPai moved from concept to a robust, enterprise‑ready MVP. The platform was built using IBM‑aligned architecture, with security, scalability and compliance embedded from the outset — including NHS, GDPR and HIPAA considerations, and secure, anonymised data handling. A structured, milestone‑driven delivery model gave full transparency to founders, partners and investors throughout the build.

Crucially, the MVP wasn’t developed in isolation. Early engagement with clinicians ensured the product reflected real‑world use, helping refine both functionality and value proposition.

Early outcomes include:

Validation with private GP practices and occupational health providers A growing pipeline of early adopters across the UK and Australia A clear roadmap for advanced AI features and future integrations

The result is a product that demonstrates genuine value to clinicians and patients — not just technical promise.

Vivolution supported GPai across multiple dimensions of its early journey.

This included:

• Securing £250k SEIS pre‑seed investment
• Allocating funding across product delivery and commercial validation
• Providing access to enterprise‑grade software delivery capability
• Supporting investment readiness, due diligence and stakeholder engagement

By combining financial clarity, disciplined delivery and real‑world validation, GPai moved quickly while significantly reducing execution and investment risk.

The business is now well positioned for £500k+ follow‑on investment, supported by increased investor confidence and a clear plan for scale.

With a validated MVP and early market traction, GPai is focused on expanding adoption across primary care and occupational health settings, while continuing to evolve its AI capabilities.

The next phase centres on scaling responsibly, deepening clinical impact, strengthening commercial routes to market and securing follow‑on investment to support growth.

Vivolution supported GPai through strategic decision support, investment readiness and value planning, and AI‑enabled software delivery, providing a fully de‑risked pathway from idea to MVP.

We combined financial clarity and control, enterprise‑grade delivery partners and commercial validation to help GPai build a credible product, attract early users and prepare for follow‑on investment.